EUCTR2017-003351-38-IT进行中（未招募）1 期
A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent ß Thalassemia
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age =18 and =35 years of age.
- •2. Able to provide written informed consent.
- •3. Diagnosis of transfusion-dependent ß-thalassemia (TDT) as defined by:
- •a. Documented homozygous ß-thalassemia (with the exception of the ß0/ß0 genotype) or compound heterozygous ß-thalassemia including ß-thalassemia/hemoglobin E (HbE). Subjects can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning. The ß0/ß0 genotypes are defined using the HbVar Database.
- •b. A history of at least 100 mL/kg/year or 10 units/year of packed Red Blood Cell (RBC) transfusions in the prior 2 years before signing the consent.
- •4. Karnofsky performance status of =80%.
- •5. Eligible for autologous stem cell transplant as per investigator’s judgment.
- •6. Access to detailed medical records on packed RBC transfusions, including volume or units of packed RBCs and associated pre-transfusion Hb values, and in-patient hospitalizations, for at least the 2 years prior to consent.
- •7. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at least 1 ovary, and is less than 1 year postmenopausal) must agree to use acceptable method(s) of contraception from consent through at least 6 months after CTX001 infusion.
- •8. Male subjects must agree to use effective contraception (including condoms) from start of busulfan conditioning through at least 6 months after CTX001 infusion.
- •9. Willing to participate in an additional long-term follow-up study or registry after completion of this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. An available 10/10 Human Leukocyte Antigen (HLA)-matched related donor.
- •2. Prior allo-hematopoietic stem cell transplant (HSCT).
- •3. Subjects with associated a-thalassemia and >1 alpha chain deletion.
- •4. Subjects with a ß0/ß0 thalassemia genotype or sickle cell beta thalassemia variant
- •5. Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator.
- •6. White blood cell (WBC) count <3 × 10^9/L or platelet count <50 × 10^9/L not related to hypersplenism.
- •7. History of a significant bleeding disorder.
- •8. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to: history of relevant drug allergies; history of cardiovascular or central nervous system disease; history or presence of clinically significant pathology; or history of mental disease.
- •9. Any prior or current malignancy or myeloproliferative disorder or a significant immunodeficiency disorder.
- •10. Advanced liver disease, defined as:
- •a. Aspartate transaminase (AST), alanine transaminase (ALT) >3 x the upper limit of normal (ULN), or direct bilirubin value >2 x the ULN, or:
- •b. Baseline prothrombin time (International Normalized Ratio; INR) >1.5 x ULN, or
- •c. History of cirrhosis or any evidence of bridging fibrosis, or active hepatitis on liver biopsy. Liver biopsy is required when liver iron concentration (LIC) is =15 mg/g on T2* MRI of liver. If a liver biopsy has been performed less than 6 months prior to consent, it does not need to be repeated.
- •11. A cardiac T2* <10 ms by MRI or left ventricular ejection fraction (LVEF) <45% by echocardiogram.
- •12. Baseline estimated glomerular filtration rate <60 mL/min/1.73 m^2.
- •13. Diffusing capacity of the lungs for carbon monoxide (DLco) <50% of predicted (corrected for hemoglobin and/or alveolar volume).
- •14. Prior treatment with gene therapy.
- •15. Intolerance or known sensitivity to plerixafor, granulocyte colony stimulating factor (G-CSF) products (e.g., filgrastim), or busulfan. Prior anaphylaxis with excipients of CTX001 product (Dimethyl sulfoxide [DMSO], Dextran).
- •16. Positive serology for human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2), hepatitis B virus (HBV; hepatitis B core antibody [HBcAb] and positive HBV polymerase chain reaction [PCR]), or hepatitis C virus (HCV) (positive HCV PCR). Positive serology for syphilis, toxoplasmosis or any other infectious disease marker as required by local testing for cellular processing.
- •17. Participation in another clinical study with an investigational drug within 30 days of screening or fewer than 5 half-lives of the investigational agent, whichever is longer from screening.
- •18. An assessment by the investigator that the subject would not comply with the study procedures outlined in the protocol.
- •19. Pregnant or breastfeeding females.
研究者
相似试验
进行中（未招募）
1 期
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat beta-thalassemiaEUCTR2017-003351-38-GBVertex Pharmaceuticals Incorporated45
进行中（未招募）
1 期
ot availableStaphylococcus aereus BacteremiaMedDRA version: 19.1Level: LLTClassification code 10058887Term: Staphylococcus aureus bacteremiaSystem Organ Class: 100000004862EUCTR2015-003510-25-DEXBiotech USA, Inc.52
进行中（未招募）
不适用
A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients - GFM-Aza intensifEUCTR2010-020341-27-FRGroupe Francophone des Myélodysplasies
招募中
3 期
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in subjects with Transfusion-Dependent β-Thalassemia2024-516894-57-00Vertex Pharmaceuticals Inc.5
已完成
1 期
A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone and in Combination with 5-Fluorouracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell CarcinomaACTRN12615001017516Ascend Biopharmaceutical Ltd.16